Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer

Yuichiro Miyoshi, Tadahiko Shien, Akiko Ogiya, Naoko Ishida, Kieko Yamazaki, R. I.E. Horii, Yoshiya Horimoto, Norikazu Masuda, Hiroyuki Yasojima, Touko Inao, Tomofumi Osako, Masato Takahashi, Nobumoto Tomioka, Yumi Wanifuchi-Endo, Mitsuchika Hosoda, Hiroyoshi Doihara, Hiroko Yamashita

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The value of assessing tumor infiltrating lymphocytes (TILs) in estrogen receptor (ER) positive/human epidermal growth factor receptor type 2 (HER2) negative breast cancer has yet to be determined. In the present study, a total of 184 cases with early distant recurrence detected within 5 years following the primary operation, 134 with late distant recurrence diagnosed following 5 years or longer and 321 controls without recurrence for >10 years following starting the initial treatment for ER-positive/HER2 negative breast cancer, registered in 9 institutions, were analyzed. The distributions of TILs and their clinical relevance were investigated. TIL distributions did not differ significantly among the early, late and no recurrence groups, employing a 30% cut-off point as a dichotomous variable. In those who had received adjuvant chemotherapy as well as endocrine therapy, a trend toward higher TIL proportions was detected when the early recurrence group was compared with the no recurrence group employing the 30% cut-off point (P=0.064). The TIL distributions were significantly associated with nodal metastasis (P=0.004), ER status (P=0.045), progesterone receptor (PgR) status (P=0.002), tumor grade (P=0.021), and the Ki67 labeling index (LI) (P=0.002) in the no recurrence group and with the Ki67 LI in the recurrence groups (P=0.002 in early recurrence group, P=0.023 in late recurrence group). High TIL distributions also predicted shorter survival time following the detection of recurrence (P=0.026). However, these prognostic interactions were not significant in multivariate analysis (P=0.200). The present retrospective study demonstrated no significant interaction between TIL proportions and the timing of recurrence. However, higher TIL proportions were observed in breast cancer patients with aggressive biological phenotypes, which tended to be more responsive to chemotherapy. The clinical relevance of stromal TILs for identifying patients who would likely benefit from additional therapies merits further investigation in a larger patient population.

Original languageEnglish
Pages (from-to)2177-2186
Number of pages10
JournalOncology Letters
Volume17
Issue number2
DOIs
Publication statusPublished - Feb 1 2019

Fingerprint

Tumor-Infiltrating Lymphocytes
Estrogen Receptors
Breast Neoplasms
Recurrence
human ERBB2 protein
Progesterone Receptors
Adjuvant Chemotherapy

Keywords

  • Breast cancer
  • Estrogen receptor positive
  • Human epidermal growth factor receptor type 2 negative
  • Prognosis
  • Tumor infiltrating lymphocytes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer. / Miyoshi, Yuichiro; Shien, Tadahiko; Ogiya, Akiko; Ishida, Naoko; Yamazaki, Kieko; Horii, R. I.E.; Horimoto, Yoshiya; Masuda, Norikazu; Yasojima, Hiroyuki; Inao, Touko; Osako, Tomofumi; Takahashi, Masato; Tomioka, Nobumoto; Wanifuchi-Endo, Yumi; Hosoda, Mitsuchika; Doihara, Hiroyoshi; Yamashita, Hiroko.

In: Oncology Letters, Vol. 17, No. 2, 01.02.2019, p. 2177-2186.

Research output: Contribution to journalArticle

Miyoshi, Y, Shien, T, Ogiya, A, Ishida, N, Yamazaki, K, Horii, RIE, Horimoto, Y, Masuda, N, Yasojima, H, Inao, T, Osako, T, Takahashi, M, Tomioka, N, Wanifuchi-Endo, Y, Hosoda, M, Doihara, H & Yamashita, H 2019, 'Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer', Oncology Letters, vol. 17, no. 2, pp. 2177-2186. https://doi.org/10.3892/ol.2018.9853
Miyoshi, Yuichiro ; Shien, Tadahiko ; Ogiya, Akiko ; Ishida, Naoko ; Yamazaki, Kieko ; Horii, R. I.E. ; Horimoto, Yoshiya ; Masuda, Norikazu ; Yasojima, Hiroyuki ; Inao, Touko ; Osako, Tomofumi ; Takahashi, Masato ; Tomioka, Nobumoto ; Wanifuchi-Endo, Yumi ; Hosoda, Mitsuchika ; Doihara, Hiroyoshi ; Yamashita, Hiroko. / Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer. In: Oncology Letters. 2019 ; Vol. 17, No. 2. pp. 2177-2186.
@article{3757d13b50b2448ca02353867b38db47,
title = "Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer",
abstract = "The value of assessing tumor infiltrating lymphocytes (TILs) in estrogen receptor (ER) positive/human epidermal growth factor receptor type 2 (HER2) negative breast cancer has yet to be determined. In the present study, a total of 184 cases with early distant recurrence detected within 5 years following the primary operation, 134 with late distant recurrence diagnosed following 5 years or longer and 321 controls without recurrence for >10 years following starting the initial treatment for ER-positive/HER2 negative breast cancer, registered in 9 institutions, were analyzed. The distributions of TILs and their clinical relevance were investigated. TIL distributions did not differ significantly among the early, late and no recurrence groups, employing a 30{\%} cut-off point as a dichotomous variable. In those who had received adjuvant chemotherapy as well as endocrine therapy, a trend toward higher TIL proportions was detected when the early recurrence group was compared with the no recurrence group employing the 30{\%} cut-off point (P=0.064). The TIL distributions were significantly associated with nodal metastasis (P=0.004), ER status (P=0.045), progesterone receptor (PgR) status (P=0.002), tumor grade (P=0.021), and the Ki67 labeling index (LI) (P=0.002) in the no recurrence group and with the Ki67 LI in the recurrence groups (P=0.002 in early recurrence group, P=0.023 in late recurrence group). High TIL distributions also predicted shorter survival time following the detection of recurrence (P=0.026). However, these prognostic interactions were not significant in multivariate analysis (P=0.200). The present retrospective study demonstrated no significant interaction between TIL proportions and the timing of recurrence. However, higher TIL proportions were observed in breast cancer patients with aggressive biological phenotypes, which tended to be more responsive to chemotherapy. The clinical relevance of stromal TILs for identifying patients who would likely benefit from additional therapies merits further investigation in a larger patient population.",
keywords = "Breast cancer, Estrogen receptor positive, Human epidermal growth factor receptor type 2 negative, Prognosis, Tumor infiltrating lymphocytes",
author = "Yuichiro Miyoshi and Tadahiko Shien and Akiko Ogiya and Naoko Ishida and Kieko Yamazaki and Horii, {R. I.E.} and Yoshiya Horimoto and Norikazu Masuda and Hiroyuki Yasojima and Touko Inao and Tomofumi Osako and Masato Takahashi and Nobumoto Tomioka and Yumi Wanifuchi-Endo and Mitsuchika Hosoda and Hiroyoshi Doihara and Hiroko Yamashita",
year = "2019",
month = "2",
day = "1",
doi = "10.3892/ol.2018.9853",
language = "English",
volume = "17",
pages = "2177--2186",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer

AU - Miyoshi, Yuichiro

AU - Shien, Tadahiko

AU - Ogiya, Akiko

AU - Ishida, Naoko

AU - Yamazaki, Kieko

AU - Horii, R. I.E.

AU - Horimoto, Yoshiya

AU - Masuda, Norikazu

AU - Yasojima, Hiroyuki

AU - Inao, Touko

AU - Osako, Tomofumi

AU - Takahashi, Masato

AU - Tomioka, Nobumoto

AU - Wanifuchi-Endo, Yumi

AU - Hosoda, Mitsuchika

AU - Doihara, Hiroyoshi

AU - Yamashita, Hiroko

PY - 2019/2/1

Y1 - 2019/2/1

N2 - The value of assessing tumor infiltrating lymphocytes (TILs) in estrogen receptor (ER) positive/human epidermal growth factor receptor type 2 (HER2) negative breast cancer has yet to be determined. In the present study, a total of 184 cases with early distant recurrence detected within 5 years following the primary operation, 134 with late distant recurrence diagnosed following 5 years or longer and 321 controls without recurrence for >10 years following starting the initial treatment for ER-positive/HER2 negative breast cancer, registered in 9 institutions, were analyzed. The distributions of TILs and their clinical relevance were investigated. TIL distributions did not differ significantly among the early, late and no recurrence groups, employing a 30% cut-off point as a dichotomous variable. In those who had received adjuvant chemotherapy as well as endocrine therapy, a trend toward higher TIL proportions was detected when the early recurrence group was compared with the no recurrence group employing the 30% cut-off point (P=0.064). The TIL distributions were significantly associated with nodal metastasis (P=0.004), ER status (P=0.045), progesterone receptor (PgR) status (P=0.002), tumor grade (P=0.021), and the Ki67 labeling index (LI) (P=0.002) in the no recurrence group and with the Ki67 LI in the recurrence groups (P=0.002 in early recurrence group, P=0.023 in late recurrence group). High TIL distributions also predicted shorter survival time following the detection of recurrence (P=0.026). However, these prognostic interactions were not significant in multivariate analysis (P=0.200). The present retrospective study demonstrated no significant interaction between TIL proportions and the timing of recurrence. However, higher TIL proportions were observed in breast cancer patients with aggressive biological phenotypes, which tended to be more responsive to chemotherapy. The clinical relevance of stromal TILs for identifying patients who would likely benefit from additional therapies merits further investigation in a larger patient population.

AB - The value of assessing tumor infiltrating lymphocytes (TILs) in estrogen receptor (ER) positive/human epidermal growth factor receptor type 2 (HER2) negative breast cancer has yet to be determined. In the present study, a total of 184 cases with early distant recurrence detected within 5 years following the primary operation, 134 with late distant recurrence diagnosed following 5 years or longer and 321 controls without recurrence for >10 years following starting the initial treatment for ER-positive/HER2 negative breast cancer, registered in 9 institutions, were analyzed. The distributions of TILs and their clinical relevance were investigated. TIL distributions did not differ significantly among the early, late and no recurrence groups, employing a 30% cut-off point as a dichotomous variable. In those who had received adjuvant chemotherapy as well as endocrine therapy, a trend toward higher TIL proportions was detected when the early recurrence group was compared with the no recurrence group employing the 30% cut-off point (P=0.064). The TIL distributions were significantly associated with nodal metastasis (P=0.004), ER status (P=0.045), progesterone receptor (PgR) status (P=0.002), tumor grade (P=0.021), and the Ki67 labeling index (LI) (P=0.002) in the no recurrence group and with the Ki67 LI in the recurrence groups (P=0.002 in early recurrence group, P=0.023 in late recurrence group). High TIL distributions also predicted shorter survival time following the detection of recurrence (P=0.026). However, these prognostic interactions were not significant in multivariate analysis (P=0.200). The present retrospective study demonstrated no significant interaction between TIL proportions and the timing of recurrence. However, higher TIL proportions were observed in breast cancer patients with aggressive biological phenotypes, which tended to be more responsive to chemotherapy. The clinical relevance of stromal TILs for identifying patients who would likely benefit from additional therapies merits further investigation in a larger patient population.

KW - Breast cancer

KW - Estrogen receptor positive

KW - Human epidermal growth factor receptor type 2 negative

KW - Prognosis

KW - Tumor infiltrating lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=85059644438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059644438&partnerID=8YFLogxK

U2 - 10.3892/ol.2018.9853

DO - 10.3892/ol.2018.9853

M3 - Article

AN - SCOPUS:85059644438

VL - 17

SP - 2177

EP - 2186

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 2

ER -